ProtecT: fifteen-year outcomes after monitoring, surgery or radiotherapy for prostate cancer
Fifteen years on, ProtecT still found no difference in prostate cancer deaths between monitoring, surgery and radiotherapy, with about 97 percent of men alive from their cancer in every group, confirming that many men can defer or avoid treatment.
Overview
Fifteen-year follow-up of the 1,643 men randomised in ProtecT to active monitoring, prostatectomy or radiotherapy.
Prostate cancer-specific mortality was 3.1 percent with monitoring, 2.2 percent with surgery and 2.9 percent with radiotherapy (no significant difference); metastases occurred in 9.4, 4.7 and 5.0 percent respectively; about a quarter of men in the monitoring group remained untreated at 15 years.
- Fifteen-year prostate cancer mortality 3.1 percent (monitoring), 2.2 percent (surgery), 2.9 percent (radiotherapy).
- Metastatic disease 9.4 percent vs 4.7 percent vs 5.0 percent.
Long-term data support active surveillance as a safe choice for low and much intermediate-risk disease, while the lower metastasis rate with treatment informs the discussion for men with longer life expectancy.
- Trial design predates MRI-based diagnosis and modern surveillance protocols.
Similar pages
not linked directly; found by shared links- Key paperProtecT: 10-year outcomes after monitoring, surgery or radiotherapy for localised prostate cancer
Shares ProtecT, Localised prostate cancer, very low and low risk, Localised prostate cancer, intermediate risk, New England Journal of Medicine.
- Key paperRTOG 9408: radiotherapy with short-term androgen deprivation for localised prostate cancer
Shares Localised prostate cancer, intermediate risk, New England Journal of Medicine.
- Key paperD'Amico risk groups: biochemical outcome after radical prostatectomy, external beam radiotherapy or brachytherapy
Shares Localised prostate cancer, very low and low risk, Localised prostate cancer, intermediate risk.
- Key paperPRECISION: MRI-targeted or standard biopsy for prostate cancer diagnosis
Shares Localised prostate cancer, very low and low risk, New England Journal of Medicine.
- TrialPACE-B
Shares Localised prostate cancer, very low and low risk, Localised prostate cancer, intermediate risk.
- TrialCHHiP
Shares Localised prostate cancer, very low and low risk, Localised prostate cancer, intermediate risk.
- TreatmentDecipher Prostate
Shares Localised prostate cancer, very low and low risk, Localised prostate cancer, intermediate risk.
- TermGleason score / Grade Group
Shares Localised prostate cancer, very low and low risk, Localised prostate cancer, intermediate risk.